Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)

Status Withdrawn

Clinical Trial Summary

Chronic posttraumatic stress disorder (PTSD) is a debilitating disorder and treatment response to pharmacological interventions has been modest for these patients. Chronic elevated anxiety and associated psychophysiological parameters including increased heart rate and alterations in skin conductance are key symptoms of chronic PTSD. Antidepressants, including selective serotonin reuptake inhibitors (SRIs) or norepinephrine-serotonin re-uptake inhibitors are considered treatment of first choice for these patients, however a substantial portion of patients do not respond sufficiently (Zhang and Davidson 2007). Therefore, there is a need to establish novel and effective add-on treatment strategies for these patients. Recently, atypical neuroleptics have received considerable attention since it was shown in multiple controlled and naturalistic trials that these medications are an effective treatment option for patients with PTSD (Davis et al 2006). In chronic PTSD, the psychophysiological responses at baseline and in response to treatment have yet been inadequately studied and may provide novel insight into antidepressant and anxiolytic mechanisms of medications used in the treatment of PTSD. Therefore, in addition to evaluating the antidepressant and anxiolytic effects of paliperidone, a novel atypical neuroleptic, in the treatment of PTSD, we also aim to compare neurophysiological responses at baseline with post-treatment effects in antidepressant-refractory PTSD patients.

Primary Aim 1: Evaluate the anxiolytic and antidepressant effects of paliperidone in patients with PTSD.

Secondary Aim 2: Evaluate the effects of paliperidone on fear conditioned psychophysiological responses (including startle eyeblink, skin conductance, and cardiovascular inter-beat interval) at baseline and after 6 weeks of naturalistic treatment in chronic PTSD patients.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00766064
Study type	Interventional
Source	Yale University
Contact
Status	Withdrawn
Phase	Phase 4
Start date	September 2008
Completion date	November 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03384706` - A Comparison of CPT Versus ART Versus WL	N/A
Completed	`NCT03418129` - Neuromodulatory Treatments for Pain Management in TBI	N/A
Completed	`NCT03129204` - Sensation Awareness Focused Training for Spouses	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Completed	`NCT05113277` - Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention	N/A
Recruiting	`NCT05327504` - Written Exposure Therapy for Veterans With SUD and PTSD	N/A
Recruiting	`NCT05843695` - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety	N/A
Active, not recruiting	`NCT05530642` - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel	N/A
Completed	`NCT00644423` - Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)	N/A
Completed	`NCT02989987` - NET for SGBV Survivors in Eastern DR Congo	N/A
Completed	`NCT02320799` - Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya	N/A
Recruiting	`NCT02293291` - Thermal Clinic Treatment in Gulf War Illness	Phase 1/Phase 2
Completed	`NCT02242136` - Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants	N/A
Completed	`NCT01911585` - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure	N/A
Completed	`NCT02720497` - The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD	N/A
Completed	`NCT01693978` - Contingency Outcomes in Prolonged Exposure	N/A
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A
Completed	`NCT01469754` - Longitudinal Survey Analysis in Lymphoma Survivors	N/A
Completed	`NCT02362477` - Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD	Phase 3
Terminated	`NCT01239173` - Emotional Memory Reactivation in Posttraumatic Stress Disorder	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.